Karyopharm XPOVIO FDA Accelerated Approval DLBCL 2020

Karyopharm Therapeutics presents XPOVIO (selinexor) following FDA accelerated approval for diffuse large B-cell lymphoma treatment. The presentation discusses commercial opportunity, market size projections, and expected U.S. sales for this selective inhibitor of nuclear export. Leadership from the company outlines clinical benefits and future regulatory milestones for the XPOVIO franchise.